Quick Takeaways
- Lombard Odier Asset Management (USA) Corp filed SCHEDULE 13G/A for Silence Therapeutics plc Ordinary Shares, par value GBP 0.05 per share (the "Shares").
- Disclosed ownership: 4.2%.
- Date of event: 31 Dec 2025.
Lombard Odier Asset Management (USA) Corp - 31 Dec 2025 SCHEDULE 13G/A Report for Silence Therapeutics plc Ordinary Shares, par value GBP 0.05 per share (the "Shares")
- Filing Manager
- Lombard Odier Asset Management (USA) Corp
- Reporting Manager
- Lombard Odier Asset Management (USA) Corp
- Shares outstanding
- 141,332,262 shares
- Disclosed Ownership
- 5,935,955 shares
- Ownership
- 4.2%
- Form type
- SCHEDULE 13G/A
- Filing time
- 09 Feb 2026, 13:16:36 UTC
- Date of event
- 31 Dec 2025
- Previous filing
- 11 Feb 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Lombard Odier Asset Management (USA) Corp disclosed 4.2% ownership in Silence Therapeutics plc Ordinary Shares, par value GBP 0.05 per share (the "Shares") on 31 Dec 2025."
What Changed
- Previous schedule filing date: 11 Feb 2025.
- Current filing was accepted on 09 Feb 2026, 13:16.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Lombard Odier Asset Management (USA) Corp | 4.2% | 5,935,955 | 0 | 5,935,955 | /s/ Elyse Strauss | Authorized Signatory |